Skip to main content
Premium Trial:

Request an Annual Quote

Orchid Posts Flat Q2 Revenues, Narrowed Loss

NEW YORK, Aug, 7 (GenomeWeb News) - Orchid Biosciences to reported flat revenue in the second quarter amid decreased R&D spending and narrowed net loss.

 

Total revenue for the period ended June 30 was $12.4 million, unchanged from the year-ago quarter, Orchid said. However, receipts from the company's core business unit of forensic, paternity, and public health DNA testing increased 11 percent year over year.

 

R&D spending fell to $1 million, from $5 million, and net loss narrowed to $10.2 million, or $.18 per share, from $12.2 million, or $.22 per share, in the second quarter 2002.

 

Orchid said it had roughly $15.7 million in cash and cash equivalents as of June 30.

 

Click here for more information.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.